Avellino introduced the world's first DNA exam that confirms the presence of genetic indicators that are positively associated with corneal diseases, providing life-changing information for patient treatment decisions and follow-up care.
We are also pioneering CRISPR gene editing technology to manage and potentially cure diseases, such as lattice corneal dystrophy, granular corneal dystrophy, and Reis-Bucklers dystrophy.
Avellino Labs is a genetic services provider specializing in genetic diagnostics, data, and therapy development. Genetic tests like ours allow patients to discover their diseases earlier, leading to greater treatment options and overall better care.
Headquartered in Silicon Valley, California, with additional operations in Korea, Japan, China, and the UK, Avellino Labs is bringing more personalized healthcare to people around the world.